Viral Vector and Plasmid DNA Manufacturing Market, by Product Type (Viral Vector, Plasmid DNA, and Nonviral Vector), by Application (Cancer, Inherited disease, Viral Infection, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

  • Published On : Feb 2019 |
  • Pages : 169 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global Viral Vector and Plasmid DNA Manufacturing Market – Novel Approach for Disease Management

Viral vector and plasmid DNA manufacturing plays a major role in modern healthcare, as it reduces disease management price by generating a wider range of immune response types and supporting to decrease the periodic medication dosage.

The global viral vector and plasmid DNA manufacturing market size was valued at US$ 290.0 million in 2017, and is expected to exhibit a CAGR of 22.5% over the forecast period (2018 – 2026).

Figure 1. Global Viral Vector and Plasmid DNA Manufacturing Market Value (US$ Mn), by Region, 2017

viral vector and plasmid dna manufacturing market fig-1

Source: Coherent Market Insights Analysis (2019)

Increasing prevalence of cancer and inherited disorders is expected to propel growth of the viral vector and plasmid DNA manufacturing market

Viral vector and plasmid DNA manufacturing is used in application of gene therapy to diagnose and treat diseases in patients. High prevalence of cancer is expected to propel demand for gene therapy, which in turn is expected to drive the market growth. According to World Health Organization (WHO), 2012, cancer is the second leading cause of morbidity and mortality worldwide, with around 14 million new cases registered in 2012, and was responsible for 8.8 million deaths worldwide in 2015. Moreover, WHO stated that, the number of new cases of cancer is expected to rise by around 70% by the end of 2030.

Similarly, according to the International Quarterly Journal of Research in Ayurveda, published in 2010, estimated around 20 – 30% of all infant deaths are due to genetic disorders, and around 11.1% of pediatric hospital admissions are for children with inherited disorders.

Furthermore, rising awareness regarding gene therapy is propelling growth of the viral vector and plasmid DNA manufacturing market over the forecast period. For instance, in November 2018, the National Institutes of Health (NIH) launched a new initiative to accelerate adoption of gene therapy to cure around 20 million patients diagnosed with sickle cell disease.

However, complications such as risk of mutagenesis, safety and efficacy issues, and stringent regulatory framework are expected to limit the adoption of gene therapy, thereby hindering the market growth.

Figure 2. Global Viral Vector and Plasmid DNA Manufacturing Market Share (%), by Design, 2018 and 2026

viral vector and plasmid dna manufacturing market fig-2

Source: Coherent Market Insights Analysis (2019)

Increasing prevalence of viral infection in North America is expected to bolster the market growth

North America holds a dominant position in the global viral vector and plasmid DNA manufacturing market, owing to high prevalence of viral infection in the region. According to the National Center for Biotechnology Information (NCBI) report, published in December 2017, around 98 cases diagnosed with Powassan Virus were reported from 1999 to 2016, with an increase of 671% cases from 1999 to 2016.

Moreover, increasing research and development activities in the field of viral vector and plasmid DNA manufacturing is expected to enhance its demand in the near future. For instance, in April 2017, Transgene announced plans for a new clinical research collaboration of investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) with standard chemotherapy (CT) as a first-line treatment for advanced non-squamous, non-small cell lung cancer (NSCLC) in patients, which is under Phase 2 clinical trial.

Key Players

Major players operating in the global viral vector and plasmid DNA manufacturing market include, Kaneka Eurogentec S.A., FinVector, Brammer Bio, Cell and Gene Therapy Catapult, Transgene SA, FUJIFILM Diosynth Biotechnologies, Sanofi, Spark Therapeutics, Cobra Biologics, UniQure, MassBiologics, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Ltd., and Thermo Fisher Scientific, Inc.

Viral vector and plasmid DNA is product of gene therapy, which is used in diagnosis and treatment of diseases such as cancer, inherited diseases, viral infections, and others. The therapeutic DNA is introduced in host with the help of a vector. Adeno associated virus based vector are much safer as compared with others viral vectors due to its integration at same site in human genome, and has wide application in various disorders such as Alzheimer’s disease.

Market Dynamics

Increasing prevalence of cancer is a major factor driving growth of the viral vector and plasmid DNA manufacturing market. According to World Cancer Research Funds and the American Institute for Cancer Research, in 2018, there were around 18 million cases of cancer, of which around 9.5 million were in men and around 8.5 million in women, globally. Moreover, government and other organizations’ initiatives regarding awareness of gene is expected to boost growth of the market. For instance, in June 2018 Alliance for Regenerative Medicine launched ARM Foundation for Cell and Gene Medicine to educate, empower, and engage public about cell and gene medicine as a treatment option. The foundation will accelerate patient’s access to safe and curative gene therapies.

However, safety and efficacy issues, stringent regulatory framework and risk of mutagenesis are expected to limit the adoption if gene therapy, thereby hindering the market growth. For instance, some viral vectors, such as gamma-retroviruses, insert its genomes at random location on the host chromosomes, which can lead to cancer.

Key features of the study:

  • This report provides in-depth analysis of the viral vector and plasmid DNA manufacturing market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global viral vector and plasmid DNA manufacturing market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Kaneka Eurogentec S.A., FinVector, Brammer Bio, Cell and Gene Therapy Catapult, Transgene SA, FUJIFILM Diosynth Biotechnologies, Sanofi, Spark Therapeutics, Cobra Biologics, uniQure MassBiologics, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Ltd., and Thermo Fisher Scientific, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global viral vector and plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the viral vector and plasmid DNA manufacturing market

Detailed Segmentation:

  • Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:
    • Viral Vector
      • Retroviral
      • Adenoviral
      • Lentiviral
      • Adeno Associated
      • Others
    • Plasmid DNA
    • Nonviral Vector
  • Global Viral Vector and Plasmid DNA Manufacturing Market, By Application:
    • Cancer
    • Inherited Disorder
    • Viral Infection
    • Others
  • Global Viral Vector and Plasmid DNA Manufacturing Market, By Geography:
    • North America
      • By Product Type:
        • Viral Vector
          • Retroviral
          • Adenoviral
          • Lentiviral
          • Adeno Associated
          • Others
        • Plasmid DNA
        • Nonviral Vector
      • By Application:
        • Cancer
        • Inherited Disorder
        • Viral Infection
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Product Type:
        • Viral Vector
          • Retroviral
          • Adenoviral
          • Lentiviral
          • Adeno Associated
          • Others
        • Plasmid DNA
        • Nonviral Vector
      • By Application:
        • Cancer
        • Inherited Disorder
        • Viral Infection
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type:
        • Viral Vector
          • Retroviral
          • Adenoviral
          • Lentiviral
          • Adeno Associated
          • Others
        • Plasmid DNA
        • Nonviral Vector
      • By Application:
        • Cancer
        • Inherited Disorder
        • Viral Infection
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Viral Vector
          • Retroviral
          • Adenoviral
          • Lentiviral
          • Adeno Associated
          • Others
        • Plasmid DNA
        • Nonviral Vector
      • By Application:
        • Cancer
        • Inherited Disorder
        • Viral Infection
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • Viral Vector
          • Retroviral
          • Adenoviral
          • Lentiviral
          • Adeno Associated
          • Others
        • Plasmid DNA
        • Nonviral Vector
      • By Application:
        • Cancer
        • Inherited Disorder
        • Viral Infection
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Viral Vector
          • Retroviral
          • Adenoviral
          • Lentiviral
          • Adeno Associated
          • Others
        • Plasmid DNA
        • Nonviral Vector
      • By Application:
        • Cancer
        • Inherited Disorder
        • Viral Infection
        • Others
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Kaneka Eurogentec S.A.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • FinVector
    • Brammer Bio
    • Cell and Gene Therapy Catapult
    • Transgene SA
    • FUJIFILM Diosynth Biotechnologies
    • Sanofi
    • Spark Therapeutics
    • Cobra Biologics
    • uniQure
    • MassBiologics
    • 4D Molecular Therapeutics
    • Renova Therapeutics
    • Shenzhen SiBiono GeneTech Co., Ltd.
    • Thermo Fisher Scientific, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Challenges Faced By Rare Disease Drug Discovery Programs
    • Reimbursement Scenario
    • Epidemiology
    • Pest Analysis
    • Regulatory Scenario
    • Comparative Analysis Of Different Types Of Viral Systems
    • Collaborations And Agreements 
    • New Product Launches
    • Investment Opportunities
    • Strategies For Product Development And Application Pathways
    • Brand Analysis
    • Cell & Gene Therapy Manufacturing Capacities In Europe
  4. Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Viral Vector
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
        • Retroviral
        • Adenoviral
        • Lentiviral
        • Adeno Associated
        • Others
    • Plasmid DNA
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Nonviral Vector
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  5. Global Viral Vector and Plasmid DNA Manufacturing Market, By Application, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Inherited Disorder
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Viral Infection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  6. Global Viral Vector and Plasmid DNA Manufacturing Market, By Region, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  7. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      •  Kaneka Eurogentec S.A.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • FinVector
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Brammer Bio
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cell and Gene Therapy Catapult
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Transgene SA
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • FUJIFILM Diosynth Biotechnologies
        •  Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Spark Therapeutics
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cobra Biologics
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • uniQure 
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • MassBiologics
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • 4D Molecular Therapeutics
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Renova Therapeutics 
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Shenzhen SiBiono GeneTech Co., Ltd.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Thermo Fisher Scientific, Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 25 market data tables and 27 figures on "Viral Vector and Plasmid DNA Manufacturing Market - Global forecast to 2026".

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.